{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:03:36Z","timestamp":1782183816298,"version":"3.54.5"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R13CA294950"],"award-info":[{"award-number":["R13CA294950"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004802","name":"California Breast Cancer Research Program","doi-asserted-by":"publisher","award":["B30CS8521"],"award-info":[{"award-number":["B30CS8521"]}],"id":[{"id":"10.13039\/100004802","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>RISE UP (Revolutionizing Investigations to StEp Up Prevention) for breast cancer brought together leading cancer specialists, women\u2019s health providers, basic and population scientists, regulators, politicians, industry leaders, patient advocates, and more from around the world to discuss and chart a radical rethinking of breast cancer prevention and risk reduction through a lens of hormonal management across a woman\u2019s life course. The presentations at RISE UP were organized to outline a path forward by leveraging what we know about breast cancer biology, early detection, treatment, and endocrine therapy toward a better and sustainable approach for breast cancer prevention. Important conference considerations were to expand our thinking about prevention by broadly considering how the hormonal environment during different life phases or common benign conditions could be better managed to minimize breast cancer risk. This set the stage for transitioning to advances in risk prediction, promising risk-reducing agents, and biomarker-driven trials to test them. Biomarker-based trials discussed focused on 1) lower or intermittent doses of standard prevention agents, 2) drugs already approved for other health purposes, and 3) maximizing benefits from lifestyle interventions alone or in combination. Throughout RISE UP, there was a strong focus on promoting health equity, including comprehensive reproductive health access, equitable representation in clinical trials, and strategies to educate women, providers, and advocates about disparities in care and how to successfully reduce them. The meeting concluded with a competition for innovative approaches to breast cancer prevention that could be integrated into hormonal and women\u2019s health interventions. RISE UP was an innovative conference that provided a forum for cross-cutting topics in women\u2019s health that do not currently exist. The insights shared at RISE UP will be paradigm shifting in breast cancer prevention and women\u2019s health space in the years to come.<\/jats:p>","DOI":"10.1007\/s10549-025-07848-7","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:32:20Z","timestamp":1767684740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RISE UP for breast cancer 2024: conference highlights &amp; takeaways"],"prefix":"10.1007","volume":"215","author":[{"given":"Taylor","family":"Glatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Leggat-Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Heditsian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"van \u2019t Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissa","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nola","family":"Hylton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Formenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fejerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetunji T.","family":"Toriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Censi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilayo","family":"Olopade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Rhoads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"7848_CR1","doi-asserted-by":"publisher","unstructured":"\u201c2024 RISE UP for breast cancer abstract collection,\u201d Breast Cancer Res. Treat., vol. 211, no. 1, pp. 1\u201342, Jun. 2025, https:\/\/doi.org\/10.1007\/s10549-025-07692-9.","DOI":"10.1007\/s10549-025-07692-9"},{"issue":"6","key":"7848_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.contraception.2012.05.017","volume":"86","author":"KS Hall","year":"2012","unstructured":"Hall KS, Trussell J (2012) Types of combined oral contraceptives used by U.S. women. Contraception 86(6):659\u2013665. https:\/\/doi.org\/10.1016\/j.contraception.2012.05.017","journal-title":"Contraception"},{"key":"7848_CR3","unstructured":"B. Frederiksen, U. Ranji, A. Salganicoff, and M. L. Published, \u201cWomen\u2019s Sexual and Reproductive Health Services: Key Findings from the 2020 KFF Women\u2019s Health Survey,\u201d KFF. Accessed: May 09, 2025. [Online]. Available: https:\/\/www.kff.org\/womens-health-policy\/issue-brief\/womens-sexual-and-reproductive-health-services-key-findings-from-the-2020-kff-womens-health-survey\/"},{"issue":"10","key":"7848_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju255","volume":"106","author":"BL Sprague","year":"2014","unstructured":"Sprague BL et al (2014) Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 106(10):dju255. https:\/\/doi.org\/10.1093\/jnci\/dju255","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"7848_CR5","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1200\/JCO.22.02900","volume":"41","author":"M Lazzeroni","year":"2023","unstructured":"Lazzeroni M et al (2023) Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study. J Clin Oncol 41(17):3116\u20133121. https:\/\/doi.org\/10.1200\/JCO.22.02900","journal-title":"J Clin Oncol"},{"key":"7848_CR6","unstructured":"\u201cAdvancing New Standards in Reproductive Health,\u201d ANSIRH. Accessed: Sep. 30, 2025. [Online]. Available: https:\/\/www.ansirh.org\/home"},{"issue":"21","key":"7848_CR7","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1002\/cncr.25443","volume":"116","author":"SS Shinde","year":"2010","unstructured":"Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF (2010) Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 116(21):4933\u20134943. https:\/\/doi.org\/10.1002\/cncr.25443","journal-title":"Cancer"},{"issue":"1","key":"7848_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00755-6","volume":"11","author":"RJ Chehayeb","year":"2025","unstructured":"Chehayeb RJ, Odzer N, Albany RA, Ferrucci L, Sarpong D, Perez-Escamilla R, Lewis JB, Phipps AI, Meisner A, Pusztai L (2025) Breastfeeding attributable fraction of triple negative breast cancer in the US. NPJ Breast Cancer 11(1):40. https:\/\/doi.org\/10.1038\/s41523-025-00755-6","journal-title":"NPJ Breast Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07848-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07848-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07848-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:09:33Z","timestamp":1770034173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07848-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7848"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07848-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.V.V. is a founding advisor and shareholder of Exai Bio and is a part-time employee and owns stock in Agendia. H.R. reports institutional research support from AstraZeneca, Daiichi Sankyo, F. Hofmann-La Roche AG\/Genentech, Gilead Sciences, Lilly, Merck & Co., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambrx, and Greenwich Pharma and has advisory and consulting roles with Chugai, Puma, Sanofi Napo, and Mylan. OIO has financial relationships with CancerIQ, 54gene, HealthWell Solutions, and Tempus as well as research funding from Ayala Pharmaceuticals, Cepheid, Color Genomics, Novartis and Genentech. N.H. reports institutional research funding from NIH. V.B. receives funding to their institution for clinical trials: AstraZeneca, Gilead SeaGen\/Pfizer Olema; consulting fees paid for running ad boards moderating lectures speaking\/presenting fees: AstraZeneca SeaGen\/Pfizer Olema Gilead; travel support for presenting: Olema. S.F. is a consultant for: Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, Boehringer Ingelheim, EMD Serono\/Merck, Genentech\/ROCHE, Nanobiotix, Telix, EmBioSys. She has received grant\/Research support from Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex, Arcus,  DoD\u2014BCRP (#BC180476, #BC180595, BC201085P3),  NIH U54 CA 27429. L.P. has received consulting fees and honoraria for advisory board participation from Pfizer, Astra Zeneca, Merck, Bristol-Myers Squibb, Stemline-Menarini, BeiGene, Personalis, Natera, Agendia, Exact Sciences, Radionetics, and institutional research funding from Pfizer, AstraZeneca, Merck, Bristol Myers Squibb. Stock options in Ataraxis. DY reports research funding from Boehringer Ingelheim and Fusion Pharmaceuticals; and is a consultant for Martell Diagnostics. JG is an executive employee of Dana Faber Cancer Institute; participation on Fiduciary Board at American Association for Cancer Research; and participation on the Scientific Advisory Board at The James P. Wilmot Foundation, Inc. and Earli Inc. LE reports funding from Merck & Co.; participation on an advisory board for Blue Cross Blue Shield; and personal fees from UpToDate; unpaid board member of QLHC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"53"}}